Estrogen Patch Shortages Followed Label Change
Higher demand for hormone therapy after updated FDA labels has led to persistent supply gaps for many patients.
Updated on Sept. 18, 2026 in Women’s Health
Live Poll
Are you confident in the availability of your prescription medications when you need them?
As of September 2026, many patients in the United States have faced difficulty accessing estradiol patches following a surge in demand. This rise in prescriptions coincided with the federal removal of long-standing black box warnings from menopause hormone therapy labels.
Why it matters
The removal of these labels prompted a 162% increase in prescriptions over two years, quickly outpacing existing supply chains. While manufacturers are now expanding production capacity to meet this need, localized shortages remain a challenge for patients seeking treatment.
Official FDA data indicates that while the supply of estradiol patches has nearly doubled in one year, it has failed to keep pace with a 162% rise in demand. The duration of current localized shortages remains under investigation.
The players
FDA
The federal agency responsible for regulating medication safety labels and overseeing drug supply stability.
Bayer
A global pharmaceutical company that manufactures hormone therapy products including the Climara estradiol patch.
The details
The shortage stems from a rapid shift in menopause care following the FDA's decision to remove black box warnings that had been in place since 2003. Manufacturers like Amneal, Sandoz, and Bayer are responding by increasing batch sizes and adding production shifts. The FDA is also performing expedited reviews of manufacturer submissions to help expedite the replenishment of pharmacy stock.
Timeline
November 2025: FDA and HHS moved to strip boxed warnings from menopause hormone therapy.
February 2026: FDA approved the first batch of revised labels.
September 3, 2026: FDA acknowledged reports of patient difficulty accessing patches.
Health Landscape
This trend represents a pivot in the historical arc of menopause care, moving away from the restrictive clinical climate established by the 2002 Women's Health Initiative trial. It signals a broader evolution in how hormone therapy is framed for patients following updated safety research.
If you are experiencing difficulty filling a prescription, ask your pharmacist about alternative doses or generic manufacturers that may have stock available. These supply issues are worth discussing with your doctor to plan for potential gaps in your established treatment schedule.
The takeaway
The recent spike in demand for hormone therapy reflects a major change in how menopause care is approached by providers and patients. If you rely on transdermal estrogen, coordinate with your physician early to manage potential pharmacy inventory delays.
What happens next
Bayer expects temporary supply constraints on one Climara dose to persist into early 2027.
Further reading
Learn more about the latest developments in Women’s Health.
Live Poll
Are you confident in the availability of your prescription medications when you need them?
